Molecular Partners
Molecular Partners is a clinical-stage Swiss biopharmaceutical company developing proprietary DARPin protein therapeutics for oncology, including targeted alpha radiotherapies and logic-gated immune cell engagers, monetized through co-development partnerships ahead of future commercialization.
- Company typePublic
- Founded2004
- HeadquartersZürich, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Molecular Partners does
Molecular Partners is a clinical-stage biopharmaceutical company headquartered in Zurich-Schlieren, Switzerland with a US office in Cambridge, Massachusetts, founded in 2004 and publicly listed on NASDAQ and SIX Swiss Exchange under ticker MOLN. The company develops a proprietary class of multi-functional protein drugs called DARPins (Designed Ankyrin Repeat Proteins), which are small (15 kDa), engineerable binding proteins supporting multi-specificity up to six targets, tunable half-life via albumin binding, and scalable bacterial fermentation manufacturing. The pipeline centers on two platform strategies: Radio-DARPins, which use DARPins as isotope-agnostic vectors for targeted alpha radiotherapeutics (lead candidates MP0712 targeting DLL3 in small cell lung cancer and MP0726 targeting mesothelin in ovarian cancer), and Switch-DARPins, which enable logic-gated conditional immune cell activation (MP0632 for solid tumors, MP0621 for stem cell transplant conditioning). Additional clinical programs include MP0317 (FAP x CD40 tumor-localized immune agonist, currently in Phase 2 for cholangiocarcinoma) and MP0533 (tetra-specific CD33/CD123/CD70/CD3 T cell engager for AML).
The company generates no commercial product revenue and operates a partnership-driven business model, monetizing the DARPin platform through upfront payments, research funding, development milestones, and royalties. Strategic alliances include a co-development partnership with Orano Med covering 10 targeted alpha therapy programs (expanded from 4 in January 2025), a February 2026 non-exclusive manufacturing agreement with Eckert & Ziegler for Actinium-225 and Lutetium-177 payloads, and historical collaborations with Novartis (COVID-19 ensovibep program and an earlier Radio-DARPin collaboration that concluded in March 2025) and AbbVie/Allergan (ophthalmology, now terminated). With approximately CHF 79 million in cash (Q1 2026) providing runway to late 2027, Molecular Partners is positioned as a platform biotech whose value inflection depends on clinical data readouts from multiple Phase 1/2a and Phase 2 oncology programs over 2026–2027.
Molecular Partners firmographics
Firmographics- Name
- Molecular Partners
- Legal name
- Molecular Partners AG
- Website
- https://molecularpartners.com
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Molecular Partners is a clinical-stage Swiss biopharmaceutical company developing proprietary DARPin protein therapeutics for oncology, including targeted alpha radiotherapies and logic-gated immune cell engagers, monetized through co-development partnerships ahead of future commercialization.
- Ownership category
- akta.pro rank
Molecular Partners industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Molecular Partners is headquartered
LocationHeadquarters
- HQ city
- Zürich
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Molecular Partners business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Partnership Payments and Milestones: Pre-commercial biotech receiving upfront payments, research funding, development milestones, and potential royalty streams from partnership agreements. Has received combined upfront and milestone payments of approximately CHF 450 million to date from partners including Novartis and Orano Med.
- Future Product Sales: Pre-revenue company anticipating commercializing drug candidates following regulatory approvals. Multiple programs in clinical development (MP0712, MP0317, MP0533) targeting oncology indications with significant unmet need.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Molecular Partners product offering
Product offeringCore offering
Molecular Partners is a clinical-stage biopharmaceutical company that develops DARPin (Designed Ankyrin Repeat Protein) therapeutics — a proprietary class of multi-functional protein drugs — for the treatment of cancer. Its portfolio is built on two platform technologies: Radio-DARPin therapeutics (targeted alpha radiotherapeutics using isotope-agnostic vectors such as 212Pb) and Switch-DARPin logic-gated immune cell engagers, with clinical candidates targeting small cell lung cancer, AML, cholangiocarcinoma, and ovarian cancer.
Product overview
Molecular Partners is a clinical-stage biotech company pioneering DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of multi-functional protein drugs. The company's portfolio centers on two technology platforms: Radio-DARPin therapy (targeted alpha radiotherapeutics using isotope-agnostic DARPin vectors) and Switch-DARPin (logic-gated immune cell engagers for conditional activation). The clinical pipeline includes MP0712 (Phase 1/2a, DLL3-targeting Radio-DARPin for small cell lung cancer, co-developed with Orano Med), MP0317 (Phase 2, FAP x CD40 for cholangiocarcinoma and solid tumors), and MP0533 (Phase 1/2a, tetra-specific T cell engager for AML). The preclinical and research-stage portfolio includes MP0726 (Radio-DARPin for ovarian cancer), MP0632 (Switch-DARPin T cell engager for solid tumors), and MP0621 (Switch-DARPin for stem cell transplantation conditioning). Four additional undisclosed Radio-DARPin programs are in research. The company operates from Switzerland (Zurich-Schlieren headquarters) and Massachusetts (Cambridge, MA office).
Differentiator
Problem solved
Functional benefit
Products and services
- MP0712 A targeted alpha radiotherapy (Radio-DARPin) directed against DLL3 for the treatment of small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers. Delivers the potent alpha-emitting therapeutic isotope 212Pb to DLL3-expressing tumor cells. Co-developed with Orano Med.
- MP0726 A radiopharmaceutical delivering the potent alpha-emitting therapeutic isotope 212Pb to mesothelin (MSLN)-expressing tumors, particularly ovarian cancer (>80% prevalence), designed to selectively bind to an MSLN region proximal to the target cell membrane to avoid impact from shedding. Co-developed with Orano Med.
- MP0317 A tumor-localized CD40 agonist (FAP x CD40) designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP) at high density in tumor stroma. Currently in Phase 2 for cholangiocarcinoma in combination with durvalumab plus gemcitabine-cisplatin.
- MP0533 A tetra-specific T cell engager targeting CD33 x CD123 x CD70 x CD3 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS/AML). Designed to kill AML cells including leukemic stem cells while minimizing damage to healthy cells, with binding strength increasing based on number of targets engaged.
- MP0632 A logic-gated Switch-DARPin T cell engager targeting MSLN and EpCAM for ovarian cancer and other solid tumors. The CD3-engaging DARPin is conditionally activated only upon binding to both MSLN and EpCAM, enabling conditional tumor-localized immune activation, with half-life extended through an Fc domain.
- MP0621 A Switch-DARPin candidate designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation. Combines cKit targeting with conditional blockade of CD47 'do-not-eat-me' signal on HSCs via a Switch-DARPin mechanism.
Quantifiable outcome
- Phase 1 data published in Nature Cancer: tumor-localized CD40 activation with favorable safety profile in 46 patients with advanced solid tumors, 1 unconfirmed partial response, 14 cases of stable disease
- +2 more outcomes
Companies that use Molecular Partners
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles2 records
Molecular Partners technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Molecular Partners partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and legacy.
- Eckert & ZieglercoreNon-exclusive development agreement for manufacturing Radio-DARPin therapeutics using Actinium-225 and Lutetium-177 payloads. Eckert & Ziegler provides services from its facilities including newly established Alpha Laboratory in Berlin, Germany dedicated to alpha emitters. Supports expansion of radiopharmaceutical capabilities beyond existing Orano Med partnership.
- Orano MedcoreCo-development agreement for Radio-DARPin Therapies using 212Pb targeted alpha therapy technology. Initially 4 programs (DLL3/MP0712 and MSLN/MP0726), expanded in January 2025 to include 6 additional programs for total of 10 potential programs. Orano Med holds option to co-develop 2 of the 6 additional programs on 50/50 basis with commercialization rights. Molecular Partners leads development of additional programs with royalty arrangements. Shared costs for preclinical and clinical development.
- NovartislegacyOctober 2020 collaboration for DARPin candidates for COVID-19; Novartis in-licensed ensovibep (MP0420) in January 2022 receiving CHF 150 million milestone. EUA withdrawn January 2023; rights returned to Molecular Partners in January 2024. December 2021 research and collaboration agreement for Radio-DARPin Therapies concluded March 2025 with $20 million upfront payment received.
- AbbVie (Allergan)legacyDiscovery alliance in ophthalmology through AbbVie's Allergan subsidiary. Key candidate abicipar developed through registrational phase for nAMD and DME. Program provided clinical, drug design and manufacturing learnings. Discovery alliance now terminated.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Molecular Partners competitors and assessment
Company assessmentDirect peers
- Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide drug conjugates and T cell engagers (BT8009, BT7480), a novel constrained-peptide platform analogous to Molecular Partners' DARPin scaffold; both target oncology with multi-specific engineered protein constructs and pursue similar tumor-localized activation strategies.
- Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents (Illuccix, PSMA-617 generics pipeline) targeting oncology indications including prostate, kidney, and brain cancers, directly competing in the same modality space as Molecular Partners' Radio-DARPin program.
- MacroGenics: MacroGenics develops multi-specific DART and TRIDENT molecules for oncology, including T cell engagers and antibody-recruiting therapeutics; it is a clinical-stage oncology peer with comparable bispecific/multi-specific protein engineering expertise targeting similar hematologic and solid tumor indications.
- Harpoon Therapeutics: Harpoon developed tri-specific T cell engagers (HPN328, HPN217) using a ProTriTAC platform with conditional T cell activation conceptually similar to Molecular Partners' Switch-DARPin mechanism; it was acquired by Merck in 2024, providing a recent valuation reference point for clinical-stage multi-specific T cell engager platforms.
Broad incumbents
- Novartis (Pluvicto / Radioligand Therapy): Novartis is the commercial leader in radioligand therapy with Pluvicto (lutetium-177 PSMA-617) and was Molecular Partners' prior Radio-DARPin partner until March 2025; it represents both a competitive benchmark and a potential future acquirer/large-pharma partner for the Radio-DARPin pipeline.
- Lantheus Holdings: Lantheus is a specialty radiopharmaceutical company with established diagnostic imaging agents (PNT2002, Pylarify) and an emerging therapeutic pipeline; its scale and commercial radiopharma infrastructure make it a direct comparable for valuation purposes and a potential strategic acquirer.
- Bayer (Radiopharmaceuticals / Xofigo): Bayer markets Xofigo (radium-223) and acquired Noria Therapeutics and Algeta, positioning it as a strategic radiopharma incumbent; its deep oncology commercial infrastructure and target alpha therapy expertise make it comparable to Molecular Partners' Orano Med-backed Radio-DARPin approach.
- Genmab: Genmab is a commercial-stage biotechnology company specializing in bispecific antibody platforms (Duobody, Hexabody) with approved products including Rybrevant and Tecvayli, providing a profitable, scaled analog for evaluating multi-specific antibody-derived therapeutic platforms targeting oncology indications similar to Molecular Partners' pipeline.
Emerging players
- Pyxis Oncology: Pyxis Oncology is a clinical-stage oncology biotech developing antibody-drug conjugates and immuno-oncology therapeutics including tumor-localized immune activation approaches (microtubule-inhibitor ADCs and immune engager candidates), positioning it as a peer in next-generation oncology biologics with similar early-stage clinical risk profile.
- Cullinan Oncology: Cullinan Oncology is a clinical-stage oncology company developing multiple assets across modalities including T cell engagers, ADCs, and immune modulators; its diversified early-stage oncology pipeline and similar headcount/revenue scale make it a direct comparable for pipeline breadth and capital efficiency benchmarking.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Molecular Partners social profiles
Digital presenceMolecular Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular Partners leadership team
Management profileNumber of profiles
Profiles11 records
Molecular Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
Molecular Partners funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular Partners M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular Partners
What does Molecular Partners do?
Molecular Partners is a clinical-stage biopharmaceutical company that develops DARPin (Designed Ankyrin Repeat Protein) therapeutics — a proprietary class of multi-functional protein drugs — for the treatment of cancer. Its portfolio is built on two platform technologies: Radio-DARPin therapeutics (targeted alpha radiotherapeutics using isotope-agnostic vectors such as 212Pb) and Switch-DARPin logic-gated immune cell engagers, with clinical candidates targeting small cell lung cancer, AML, cholangiocarcinoma, and ovarian cancer.
Is Molecular Partners a public or private company?
Molecular Partners is a public company. It is classified as public and is currently operating.
When was Molecular Partners founded?
Molecular Partners was founded in 2004. It employs 101 to 250 people.
Where is Molecular Partners based?
Molecular Partners is headquartered in Zürich, Switzerland, in the Europe region.
How does Molecular Partners make money?
Two revenue lines are on record. Partnership Payments and Milestones are the primary driver. The others are future Product Sales.
Who are Molecular Partners's main competitors?
Direct peers on record are Bicycle Therapeutics, Telix Pharmaceuticals, MacroGenics and Harpoon Therapeutics. Broad incumbents are Novartis (Pluvicto / Radioligand Therapy), Lantheus Holdings, Bayer (Radiopharmaceuticals / Xofigo) and Genmab. Emerging players are Pyxis Oncology and Cullinan Oncology.
Does Molecular Partners have an API?
No public API is recorded for Molecular Partners.
What industry is Molecular Partners in?
Molecular Partners's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.